neomycin

Key facts

Drug.IUPAC_name: (2RS,3S,4S,5R)-5-Amino-2-(aminomethyl)-6-((2R,3S,4R,5S)-5-((1R,2R,5R,6R)-3,5-diamino-2-((2R,3S,4R,5S)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yloxy)-6-hydroxycyclohexyloxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yloxy)tetrahydro-2H-pyran-3,4-diol
Drug.image: Neomycin B C.svg
Drug.image_class: skin-invert-image
Drug.image2: Neomycin ball-and-stick.png
Drug.image_class2: bg-transparent
Drug.tradename: Neo-rx
Drug.MedlinePlus: a682274
Drug.pregnancy_US: D
Drug.legal_US: Rx-only
Drug.legal_US_comment: but OTC in Neosporin and similar ointments
Drug.routes_of_administration: Topical, oral
Drug.bioavailability: None
Drug.protein_bound: N/A
Drug.metabolism: N/A
Drug.elimination_half life: 2 to 3 hours
Drug.CAS_number: 1404-04-2
Drug.ATC_prefix: A01
Drug.ATC_suffix: AB08

via Wikipedia infobox

Wikidata facts

Show 1 more fact

Commons category: Neomycins

Sources (2)

via Wikidata · CC0

~8 min read

Article

11 sections

Contents

Discovery
Medical uses
Spectrum
Side effects
Molecular biology
Activity
Resistance
Biosynthetic pathway
Composition
DNA binding
References

Neomycin, also known as framycetin, is an aminoglycoside antibiotic that displays bactericidal activity against Gram-negative aerobic bacilli and some anaerobic bacilli where resistance has not yet arisen. It is generally not effective against Gram-positive bacilli and anaerobic Gram-negative bacilli. Neomycin comes in oral and topical formulations, including creams, ointments, and eyedrops. Neomycin belongs to the aminoglycoside class of antibiotics that contain two or more amino sugars connected by glycosidic bonds.

Neomycin was discovered in 1949 by microbiologist Selman Waksman and his student Hubert Lechevalier at Rutgers University. Neomycin received approval for medical use in 1952. Rutgers University was granted the patent for neomycin in 1957.